WBH Advisory Inc. Has $6.94 Million Stake in Eli Lilly and Company (NYSE:LLY)
WBH Advisory Inc. reduced its stake in Eli Lilly and Company (NYSE: LLY) by 6.4% in Q1, now holding 8,400 shares valued at approximately $6.94 million. Other institutional investors also adjusted their positions, with 82.53% of the stock owned by such entities. Eli Lilly's stock has seen a decline of 14.2%, with a current price of $640.17. The company reported strong earnings, with $6.31 EPS, exceeding estimates, and announced a quarterly dividend of $1.50 per share.
WBH Advisory Inc. trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,400 shares of the company's stock after selling 574 shares during the period. WBH Advisory Inc.'s holdings in Eli Lilly and Company were worth $6,938,000 as of its most recent filing with the Securities and Exchange Commission.
Get Eli Lilly and Company alerts:
- Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Garner Asset Management Corp lifted its position in Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after acquiring an additional 12 shares during the last quarter. Tobias Financial Advisors Inc. boosted its position in shares of Eli Lilly and Company by 4.1% during the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock valued at $237,000 after acquiring an additional 12 shares in the last quarter. Redwood Investments LLC boosted its holdings in Eli Lilly and Company by 0.5% during the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock valued at $1,705,000 after purchasing an additional 12 shares in the last quarter. Hobbs Wealth Management LLC grew its position in Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the period. Finally, Hixon Zuercher LLC grew its holdings in shares of Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after purchasing an additional 12 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Stock Down 14.2%
LLY stock opened at $640.17 on Friday. The firm has a 50-day moving average price of $776.36 and a 200-day moving average price of $799.60. Eli Lilly and Company has a 12 month low of $633.20 and a 12 month high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $606.71 billion, a P/E ratio of 52.09, a price-to-earnings-growth ratio of 1.06 and a beta of 0.44.
- Novo Nordisk Stock Sinks—But Is a Bottom Finally In?
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company's revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the company posted $3.92 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.
Wall Street Analysts Forecast Growth
- Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
LLY has been the topic of several research reports. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Morgan Stanley restated an "overweight" rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Leerink Partners restated a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Finally, Guggenheim increased their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a report on Friday, July 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $999.50.
Get Our Latest Report on LLY
About Eli Lilly and Company
(Free Report)Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- Roth IRA Calculator: Calculate Your Potential Returns
- Why Monolithic Power's Earnings and Guidance Ignited a Rally
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down
- How to Start Investing in Real Estate
- Microsoft Stock Gains as Analysts Boost Price Targets
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Eli Lilly and Company Right Now?
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
